Show simple item record

dc.contributor.authorJones, Sarah
dc.contributor.authorHowl, John D.
dc.date.accessioned2008-01-09T10:31:06Z
dc.date.available2008-01-09T10:31:06Z
dc.date.issued2003
dc.identifier.citationExpert Opinion on Therapeutic Targets, 7(6): 749-758
dc.identifier.issn1744-7631
dc.identifier.pmid14640910
dc.identifier.doi10.1517/14728222.7.6.749
dc.identifier.urihttp://hdl.handle.net/2436/15858
dc.descriptionMetadata only
dc.description.abstractThe past decade has witnessed a rapid expansion of our understanding of the biological roles of cannabinoids and their cognate receptors. It is now certain that Delta9-tetrahydrocannabinol, the principle psychoactive component of the Cannabis sativa plant, binds and activates membrane receptors of the 7-transmembrane domain, G-protein-coupled superfamily. Several putative endocannabinoids have since been identified, including anandamide, 2-arachidonyl glycerol and noladin ether. Synthesis of numerous cannabinomimetics has also greatly expanded the repertoire of cannabinoid receptor ligands with the pharmacodynamic properties of agonists, antagonists and inverse agonists. Collectively, these ligands have proven to be powerful tools both for the molecular characterisation of cannabinoid receptors and the delineation of their intrinsic signalling pathways. Much of our understanding of the signalling mechanisms activated by cannabinoids is derived from studies of receptors expressed by tumour cells; hence, this review provides a succinct summary of the molecular pharmacology of cannabinoid receptors and their roles in tumour cell biology. Moreover, there is now a genuine expectation that the manipulation of cannabinoid receptor systems may have therapeutic potential for a diverse range of human diseases. Thus, this review also summarises the demonstrated antitumour actions of cannabinoids and indicates possible avenues for the future development of cannabinoids as antitumour agents.
dc.language.isoen
dc.publisherTaylor & Francis (Informa Healthcare)
dc.relation.urlhttps://www.tandfonline.com/doi/abs/10.1517/14728222.7.6.749
dc.subjectCannabinoid receptor systems
dc.subjectTumours
dc.subjectIntervention
dc.subjectSignal Transduction
dc.subjectEndocannabinoid
dc.titleCannabinoid receptor systems: therapeutic targets for tumour intervention.
dc.typeJournal article
html.description.abstractThe past decade has witnessed a rapid expansion of our understanding of the biological roles of cannabinoids and their cognate receptors. It is now certain that Delta9-tetrahydrocannabinol, the principle psychoactive component of the Cannabis sativa plant, binds and activates membrane receptors of the 7-transmembrane domain, G-protein-coupled superfamily. Several putative endocannabinoids have since been identified, including anandamide, 2-arachidonyl glycerol and noladin ether. Synthesis of numerous cannabinomimetics has also greatly expanded the repertoire of cannabinoid receptor ligands with the pharmacodynamic properties of agonists, antagonists and inverse agonists. Collectively, these ligands have proven to be powerful tools both for the molecular characterisation of cannabinoid receptors and the delineation of their intrinsic signalling pathways. Much of our understanding of the signalling mechanisms activated by cannabinoids is derived from studies of receptors expressed by tumour cells; hence, this review provides a succinct summary of the molecular pharmacology of cannabinoid receptors and their roles in tumour cell biology. Moreover, there is now a genuine expectation that the manipulation of cannabinoid receptor systems may have therapeutic potential for a diverse range of human diseases. Thus, this review also summarises the demonstrated antitumour actions of cannabinoids and indicates possible avenues for the future development of cannabinoids as antitumour agents.


This item appears in the following Collection(s)

Show simple item record